A Phase 3 Randomized Double-masked Active Controlled Study to Compare the Efficacy and Safety of HLX04-O Administered by Intravitreal Injection With Ranibizumab in Subjects With Wet Age Related Macular Degeneration (wAMD)
Latest Information Update: 03 Apr 2024
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab
- Indications Wet age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Sponsors Shanghai Henlius Biotech
- 10 Jan 2022 Status changed from not yet recruiting to recruiting.
- 19 Aug 2021 New trial record